Pluristem Therapeutics, Inc. (PSTI: Quote), a developer of placenta-based cell therapies, Wednesday said the company has taken possession of and is moving into its new state-of-the-art GMP facility.
The facility allows for the production of mass quantities of PLacental eXpanded or PLX cells that possess the advantages of being grown utilizing Pluristem's patented 3D bioreactor technology.
The new manufacturing facility will have the capability to produce different PLX product candidates with the potential capacity of over 150,000 doses annually.
The new facility allows increasing the yield from one placenta to over ten times the yield from the previous pilot facility.
Additionally, if regulators approve more indications for clinical trials, this new facility will enable the firm to supply PLX cells to conduct these additional trials in parallel.
Zami Aberman, Chairman and CEO of Pluristem said, "We are excited to begin work in our new plant. With this new manufacturing facility, our company is capable of combining the ideal characteristics of a supply source in the placenta with a proprietary expansion technology that successfully addresses the issues of reproducibility and cost to provide high numbers of reproducible batches of the highest quality PLX cells.''
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org